Hyperlipoproteinemia Type II Clinical Trial
Official title:
Familial Hypercholesterolemia Non Invasive Detection in Children by Salivary Test
Familial Hypercholesterolemia is a common cause of premature coronary heart disease, it is
present in 1 per 500 to 1 per 250 people of the general population. Studies on families of
Hypercholesterolemia have shown that children with Hypercholesterolemia have a major increase
in risk of coronary heart disease after the age of 20. The difference between
Hypercholesterolemia and normal children in their atherogenic profil begin at the age of
Nowadays , systematic screening techniques are not well implemented whereas their are clear
World health organization guidelines.
International studies show treatment must be initiated early as at the age of eight years
old.
In pediatry, Parents can be reluctant to practice blood test on their children. In order to
allow more patients to be diagnosed and treated early enough to prevent major complications
we need to find an non invasive test.
The main objective is to define the level of detection of cholesterol in saliva with two
enzymatic tests. Furthermore we aim to evaluate the performance of salivary detection of
cholesterol in children.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00477594 -
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
|
Phase 2 | |
| Completed |
NCT02100839 -
Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia
|
Phase 1/Phase 2 | |
| Terminated |
NCT01841684 -
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
|
Phase 3 | |
| Completed |
NCT00552097 -
Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)
|
Phase 3 | |
| Completed |
NCT00607373 -
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT01524289 -
Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)
|
Phase 3 | |
| Completed |
NCT00694109 -
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
|
Phase 3 |